Eli Lilly and Company (LLY)vsSight Sciences Inc (SGHT)
LLY
Eli Lilly and Company
$1,433.55
-0.82%
HEALTHCARE · Cap: $1.27T
SGHT
Sight Sciences Inc
$10.59
-2.22%
HEALTHCARE · Cap: $601.92M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 97713% more annual revenue ($86.46B vs $88.39M). LLY leads profitability with a 31.9% profit margin vs -32.1%. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
SGHT
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+33.3%
Fair Value
$8.29
Current Price
$10.59
$2.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Revenue surging 25.2% year-over-year
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.7x book value
Trading at 11.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -57.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : SGHT
The strongest argument for SGHT centers on Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Bear Case : SGHT
The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
SGHT carries more volatility with a beta of 2.40 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 27/100), backed by strong 31.9% margins and 38.6% revenue growth. SGHT offers better value entry with a 33.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?